JP2024541476A5 - - Google Patents

Info

Publication number
JP2024541476A5
JP2024541476A5 JP2024531027A JP2024531027A JP2024541476A5 JP 2024541476 A5 JP2024541476 A5 JP 2024541476A5 JP 2024531027 A JP2024531027 A JP 2024531027A JP 2024531027 A JP2024531027 A JP 2024531027A JP 2024541476 A5 JP2024541476 A5 JP 2024541476A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541476A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/050934 external-priority patent/WO2023097024A1/en
Publication of JP2024541476A publication Critical patent/JP2024541476A/ja
Publication of JP2024541476A5 publication Critical patent/JP2024541476A5/ja
Pending legal-status Critical Current

Links

JP2024531027A 2021-11-24 2022-11-23 Ctla-4に対する抗体及びその使用方法 Pending JP2024541476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163282887P 2021-11-24 2021-11-24
US63/282,887 2021-11-24
PCT/US2022/050934 WO2023097024A1 (en) 2021-11-24 2022-11-23 Antibodies against ctla-4 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024541476A JP2024541476A (ja) 2024-11-08
JP2024541476A5 true JP2024541476A5 (cg-RX-API-DMAC7.html) 2025-11-19

Family

ID=84901675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531027A Pending JP2024541476A (ja) 2021-11-24 2022-11-23 Ctla-4に対する抗体及びその使用方法

Country Status (7)

Country Link
EP (1) EP4436998A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024541476A (cg-RX-API-DMAC7.html)
KR (1) KR20240123846A (cg-RX-API-DMAC7.html)
CN (1) CN119278213A (cg-RX-API-DMAC7.html)
AU (1) AU2022396272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238936A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023097024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
CN122341642A (zh) 2023-09-21 2026-07-03 多曼治疗学公司 抗ccr8单克隆抗体及其治疗用途
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
ES2706547T3 (es) * 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2017229687A1 (en) 2016-03-08 2018-09-20 Takeda Pharmaceutical Company Limited Inducible binding proteins and methods of use
EP3526257A2 (en) 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
US12559565B2 (en) * 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof

Similar Documents

Publication Publication Date Title
JP7862028B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP7809680B2 (ja) 癌処置のための多重特異性結合タンパク質
JP2022541435A5 (cg-RX-API-DMAC7.html)
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
JP2023518134A5 (cg-RX-API-DMAC7.html)
JP2022523781A5 (cg-RX-API-DMAC7.html)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP2019513370A5 (cg-RX-API-DMAC7.html)
JP2022504802A5 (cg-RX-API-DMAC7.html)
JP2022504822A5 (cg-RX-API-DMAC7.html)
IL302278A (en) Combination treatment
JP2022525478A5 (cg-RX-API-DMAC7.html)
JP2018533371A5 (cg-RX-API-DMAC7.html)
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白;TRAAFFIAA)
IL304898A (en) New anti-CD24 antibodies
JP2020522267A (ja) 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2022542559A5 (cg-RX-API-DMAC7.html)
JP2024539506A5 (cg-RX-API-DMAC7.html)
US20230235064A1 (en) Bispecific immune cell engagers with binding specificity for hla-g and another antigen
JP2021523949A5 (cg-RX-API-DMAC7.html)
JP2024504162A5 (cg-RX-API-DMAC7.html)
IL316226A (en) Anti-ror1 antibody and ror1-targeting engineered cells
JP2024539630A5 (cg-RX-API-DMAC7.html)
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2025528835A5 (cg-RX-API-DMAC7.html)